Eosinophilic gastroenteritis (EGE) is a distinct eosinophil-predominant inflammatory process in gastric or small intestinal mucosal biopsies. Although most published material has focused largely on the pediatric population, this manuscript focuses on the adult with EGE. Most often in adults, EGE is detected during endoscopic investigation for abdominal pain or diarrhea. Other causes of gastric and intestinal mucosal eosinophilia require exclusion, including parasitic infections and drug-induced causes. Occasionally, the muscle wall or serosal surface may be involved. EGE appears to be more readily recognized, in large part, due to an evolution in the imaging methods used to evaluate abdominal pain and diarrhea. Other causes of gastric and intestinal mucosal eosinophilia require exclusion, including parasitic infections and drug-induced causes. Occasionally, the muscle wall or serosal surface may be involved. EGE appears to be more readily recognized, in large part, due to an evolution in the imaging methods used to evaluate abdominal pain and diarrhea. In one specific classification schema that included different forms of intestinal eosinophilic infiltration, involvement of the muscular layer or serosa was also described, but even in these, concomitant mucosal involvement was often present.

Eosinophilic gastroenteritis (EGE) is a distinct eosinophil-predominant inflammatory process in gastric or small intestinal mucosal biopsies. Although most published material has focused largely on the pediatric population, this manuscript focuses on the adult with EGE. Most often in adults, EGE is detected during endoscopic investigation for abdominal pain or diarrhea. Other causes of gastric and intestinal mucosal eosinophilia require exclusion, including parasitic infections and drug-induced causes. Occasionally, the muscle wall or serosal surface may be involved. EGE appears to be more readily recognized, in large part, due to an evolution in the imaging methods used to evaluate abdominal pain and diarrhea. In one specific classification schema that included different forms of intestinal eosinophilic infiltration, involvement of the muscular layer or serosa was also described, but even in these, concomitant mucosal involvement was often present.

EGE has been considered an uncommon, even rare disorder but this may well depend on its definition as well as the method of detection. In a single clinical practice, only less than 1% of all upper endoscopic studies during an 8-year period showed changes that led to a diagnosis of EGE. Biopsies are now commonly done during routine endoscopic evaluation, even if the mucosa is visually normal or if only non-specific changes are present. Finally, it is speculated that there may be some environmental factors (or allergen) in the diet or air that plays a critical role in the emergence of an eosinophil-predominant mucosal inflammatory process.

HISTOPATHOLOGICAL CRITERIA

Most often, the diagnosis of EGE is defined by histological evaluation of endoscopic biopsies. There are some potential diagnostic issues and pitfalls. First,
pathologists, like endoscopists, have varying levels of expertise in mucosal biopsy interpretation. It is appreciated that there may be many “shades of grey” in the definition of EGE and the experience of the pathologist may determine disease recognition. To date, however, precise information on intra- and inter-observer error in the interpretation of biopsies in EGE is still needed. Second, eosinophils may normally be detected in the gastric and intestinal mucosa (as opposed to the normal esophagus), and only limited numbers of studies (mainly in children) have tried to quantify normal compared to abnormal numbers in health and different inflammatory disease states, e.g. ulcerative colitis[7,8].

Third, these studies are also limited, to some degree, by the inherent “patchy” nature of the eosinophilic inflammatory process in EGE since the numbers of eosinophils may differ in biopsies obtained from different sites. Finally, fixation methods may be critical in the definition of eosinophils in gastric and intestinal biopsies. For example, Bouin’s solution (often used for gastric or intestinal biopsies), can result in “bleaching” of eosinophil granules making detection much more difficult. If EGE is suspected, routine formalin fixation has been shown to provide more optimal material for routine staining (Figure 2)[9].

**CLINICAL FEATURES**

Prior studies have suggested that EGE is a male-predominant clinical disorder[1]. Some believe that clinical features may reflect extent, location and depth of infiltration of this eosinophilic inflammatory process within the gastrointestinal tract[1,5]. Abdominal pain and diarrhea are common. Weight loss may occur, in part related to malabsorption. Iron deficiency associated with blood loss as well as protein-losing enteropathy may also be seen. If muscular layers are involved, obstruction or, even an acute abdomen has been recorded[1-4], while serosal involvement may be associated with evidence of ascites[5]. Peripheral blood eosinophilia has been recorded in up to 70%, but this is not specific for EGE and should lead to exclusion of other disorders, specifically parasitic infections[8]. In some with EGE, increased serum IgE levels may be seen, but this is also not specific. Endoscopic evaluation might permit definition of the extent of the inflammatory process in the upper gastrointestinal tract. In rare reports[10,11], celiac disease has been linked to EGE but as completely independent disorders.

Treatment is largely aimed at resolving symptoms. Medications used in EGE are largely based on empiric observation and experience. Because of the rarity of EGE, there are no controlled treatment trials available. Steroids have been used as a traditional form of therapy to reduce the inflammatory process[1-4], however, these may cause steroid-related effects, especially because of their recurring need over prolonged periods. Other remedies have been used but their effectiveness still requires definition. These include: proton pump inhibitors[9], mast cell stabilizers[12,13], ketotifen[14], leukotriene antagonists[15], octreotide[16] and surgical resection of involved intestinal segments[17]. This lengthening therapeutic list might be construed as a clear reflection of the limited forms of effective therapy that are currently available.

**HYPEREOSINOPHILIC SYNDROMES**

The hypereosinophilic syndromes (HES) represent a heterogeneous group of rare disorders that have been defined in the past by persistent blood eosinophilia for more than 6 mo with evidence of organ involvement. The cause is unknown. HES may include a broad
spectrum of disorders, including familial or genetically-based eosinophilia and more sinister neoplastic disorders, including eosinophilic leukemia[1,19]. About 25% of cases with HES, however, have eosinophilic infiltration in the gastrointestinal tract, and in some, this inflammatory process is reportedly localized only in gastric or intestinal mucosa.

The onset of HES is generally described between ages of 20 and 50 years with a male predominance[1]. Abdominal pain and diarrhea with malabsorption have been described. In comparison with those with disease localized in some other non-intestinal sites, involvement of the intestinal tract has been associated with a limited prognosis, lympho-proliferative disorders[20], and, in some, a fatal outcome[8]. Unfortunately, there may be little to distinguish EGE and HES, especially if the latter is early in the clinical course and localized to the gastric and intestinal mucosa alone. In some, steroids, immune-suppressants and even biological agents have been used[21]. Clearly, long-term clinical studies are needed to define and elucidate the natural history of EGE, a relatively unique inflammatory process, and to determine if there is a potential HES risk.

REFERENCES
1Straumann A. Idiopathic eosinophilic gastrointestinal diseases in adults. Best Pract Res Clin Gastroenterol 2008; 22: 481-496
2Cello JP. Eosinophilic gastroenteritis—a complex disease entity. Am J Med 1979; 67: 1097-1104
3Talley NJ, Shorter RG, Phillips SF, Zinsmeister AR. Eosinophilic gastroenteritis: a clinicopathological study of patients with disease of the mucosa, muscle layer, and subserosal tissues. Gut 1990; 31: 54-58
4Khan S, Orenstein SR. Eosinophilic gastroenteritis. Gastroenterol Clin North Am 2008; 37: 333-348
5Klein NC, Hargrove RL, Sleisenger MH, Jeffries GH. Eosinophilic gastroenteritis. Medicine (Baltimore) 1970; 49: 299-319
6Gorrepati N, Desai H, Fox S, Amin M, Steevic V, Desai T. An eight-year study of 30 consecutive patients with eosinophilic gastroenteritis in one gastroenterology practice: eosinophilic gastroenteritis is more common than previously appreciated and may not necessarily require corticosteroid therapy. Gastroenterology 2007; 132: A610 (Abstract)
7Lowichick A, Weinberg AG. A quantitative evaluation of mucosal eosinophils in the pediatric gastrointestinal tract. Mod Pathol 1996; 9: 110-114
8DeBrosse CW, Case JW, Putnam PE, Collins MH, Rothenberg ME. Quantity and distribution of eosinophils in the gastrointestinal tract of children. Pediat Dev Pathol 2006; 9: 210-218
9Freeman HJ. Histologic evaluation of gastric biopsies for diagnosis and treatment in eosinophilic gastroenteritis. Can J Gastroenterol 1990; 7: 343-348
10Bennett RA, Whitecock T 3rd, Kelley JL Jr. Eosinophilic gastroenteritis, gluten enteropathy, and dermatitis herpetiformis. Am J Dig Dis 1974; 19: 1154-1161
11Butterfield JH, Murray JA. Eosinophilic gastroenteritis and gluten-sensitive enteropathy in the same patient. J Clin Gastroenterol 2002; 34: 552-553
12Moots RJ, Prouse P, Gumpel JM. Near fatal eosinophilic gastroenteritis responding to oral sodium chromoglycate. Gut 1988; 29: 1282-1285
13Di Gioacchino M, Pizzicannella G, Fini N, Falasca F, Antinucci R, Masci S, Mezzetti A, Marzio L, Cuccurullo F. Sodium cromoglycate in the treatment of eosinophilic gastroenteritis. Allergy 1990; 45: 161-166
14Melamed I, Feanny SJ, Sherman PM, Roifman CM. Benefit of ketotifen in patients with eosinophilic gastroenteritis. Am J Med 1991; 90: 310-314
15Neustrom MR, Friesen C. Treatment of eosinophilic gastroenteritis with montelukast. J Allergy Clin Immunol 1999; 104: 506
16Rausch T, Gyr K, Wegmann W, Germer M, Meier R. [Symptomatic therapy of severe diarrhea in eosinophilic gastroenteritis with the somatostatin analog octreotide (Sandostatin)]. Schweiz Med Wochenschr Suppl 1997; 89: 95-135
17Katz AJ, Goldman H, Grand RJ. Gastric mucosal biopsy in eosinophilic (allergic) gastroenteritis. Gastroenterology 1977; 73: 705-709
18Sacher P. [Surgical aspects of eosinophilic gastroenteritis (author's transl)] Z Kinderchir 1981; 34: 25-30
19Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood 1994; 83: 2759-2779
20Simon HU, Plotz SG, Dummer R, Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 1999; 341: 1112-1120
21Plotz SG, Simon HU, Darsow U, Simon D, Vassina E, Yousefi S, Hein R, Smith T, Behrendt H, Ring J. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 2003; 349: 2334-2339